Novo's Wegovy pill inherits a $32 billion franchise as a judge declines to block Lilly's ads

Novo Nordisk's▲+1.93% — Novo Nordisk, up 1.93 percent today weight-loss drugs and Ozempic, its diabetes injection, together sold about $32 billion in 2025, according to court papers filed in its false-advertising lawsuit against Eli Lilly▲+3.61% — Eli Lilly, up 3.61 percent today ¹². From Monday, November 2, France adds another carrier for that franchise: the Wegovy pill, prescription-only and unreimbursed, at recommended prices from 169 euros a month at the starting dose to 235 euros at the full dose↗ ³. The pill already sells in the United States, Britain, the UAE and, since September 1, Germany↗ ⁴.

The ad lawsuit loses its first round in Trenton

On October 26, US District Judge Zahid Quraishi denied Novo's bid for a preliminary injunction against Lilly's Zepbound and Mounjaro ads↗ ¹². Novo sued in July, arguing the spots compared higher doses of its rival's drugs against lower doses of Wegovy and Ozempic; one commercial claimed 50 pounds of average loss on Zepbound against 33 on Wegovy ¹².

The ads' market impact from April to July was "negligible," the judge found↗, with Novo's prescriptions stable ¹². He called the case "less than persuasive" on a preliminary record and did not rule on the merits ¹².

Lilly's growth runs on price, and the ruling never touched it

Lilly's October 29 quarter shows where the share moved instead ⁵. Revenue rose 39% to $24.4 billion↗, led by Mounjaro and Zepbound, its GLP-1 injections; GLP-1s mimic a gut hormone to lower blood sugar and blunt appetite ⁵. Volume rose 53% against realized prices down 15%, with prices outside the US down 29% after Mounjaro joined China's national reimbursement list ⁵.

Guidance climbed to $91 to $92 billion, from $85 to $87 billion↗, and 500,000 patients now reach Lilly's medicines through the federal Medicare GLP-1 Bridge pilot, a government plan covering these drugs for seniors, with 80% of them new to the medicines ⁵⁶. About $900 million of the quarter was one-time ⁷.

Novo's side sits in its own numbers: US injectable Wegovy sales fell 22% in the second quarter once currency moves are stripped out, and 2026 sales are guided flat to down 6% ⁵. Prescriptions a judge called stable, meeting growth like that, point to price as the lever. Lilly is buying market share with discounts; Novo is trying to reclaim it in court.

The November 4 print prices whether the pill can carry the load

Novo's case in pills is real. The company said in August, reporting second-quarter earnings, that the Wegovy pill held about 90% of the oral obesity market ⁴. Lilly's answer, Foundayo, managed $184 million in its first full quarter, below estimates and behind the Wegovy pill's volumes ⁷⁸, and a European Medicines Agency committee has now recommended it, setting up a pill-versus-pill fight in Europe ⁹.

CagriSema, Novo's next obesity drug, beat Wegovy head-to-head in late-stage testing ¹⁰. Citi▼−3.03% — Citi, down 3.03 percent today kept its neutral rating anyway, calling Lilly's retatrutide diabetes data incrementally negative for Novo, a head-to-head covered here on October 28 ¹¹.

Novo reports on November 4 at 07:30 CET ⁹. The stock is down more than 60% over two years and trades near 12 times forward earnings against 19.2 times for healthcare stocks on average ¹⁰. One line decides the week: whether oral Wegovy revenue grows faster than the US injectable shrinks. The pill has to outrun the price cut.